A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

NCT01394016 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: Abemaciclib
DRUG: Fulvestrant

Sponsor

Eli Lilly and Company